MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze RZLT →
    • FindStock Picks / Stock Screener
    • Value · RZLTIntrinsic Value Calculator
    • Invest · RZLTInvestment Case
    • Hold · RZLT5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
RZLT stock logo

RZLT

Rezolute, Inc.

$3.92
-0.28
 (-6.67%)
Exchange:  NASDAQ
Market Cap:  379.177M
Shares Outstanding:  103.907M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Nevan Charles Elam
Full Time Employees:  63
Address: 
275 Shoreline Drive
Redwood City
CA
94065
US
Website:  https://www.rezolutebio.com
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

RZLT full analysis

05/10/2026

Hey everyone, welcome back to MarketSnap. Rezolute just wrapped up its fiscal year, and this is a stock that has been absolutely brutalized over the past year — down more than fifty percent — yet it spiked almost forty percent in a single week back in June on a slice of clinical data. That kind of whiplash tells you the market is pricing this company on binary events, not steady execution. So the real question is whether the fundamentals underneath…

Listen to full analysis (audio file)

Open in MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
RZRZLT logoRZLTRezolute, Inc.379.2M——-94.7%
PHPHAT logoPHATPhathom Pharmaceuticals, Inc.378.8M——-14.9%
HEHELP logoHELPHelus Pharma Inc.378.7M——-70.8%
EPEPRX logoEPRXEupraxia Pharmaceuticals Inc.390.2M——-53.4%
AVAVTX logoAVTXAvalo Therapeutics, Inc.390.9M——-20.9%
YMYMAB logoYMABY-mAbs Therapeutics, Inc.391.2M——-27.6%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202420252026
Revenue000
Gross Profit000
EBITDA-68,423-74,381-82,935
Operating Income-70,423-79,894-82,966
Net Income-68,459-74,412-77,586

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202420252026
Total Assets132,737175,490112,849
Total Liabilities11,73413,36312,162
Total Stockholders Equity121,003162,127100,687
Total Debt2,2281,6150
Cash and Cash Equivalents70,39694,10710,615

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202420252026
Operating Cash Flow-57,368-69,075-64,635
Capital Expenditure000
Free Cash Flow-57,368-69,075-64,635
Net Income-68,459-74,412-77,586
Net Change in Cash54,36023,711-83,492

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2031Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)118,608.546Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,615,592.272Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)572,344.800Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-8,364.107Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)1,167,385.584Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)346,454.512Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-8,374.266Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)922,226.587Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)273,691.040Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)0Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)2.630Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)8.880Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-0.080Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)3Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-4.81
?Enterprise Value
 (TTM)
: 
346.148M  ?EV/FCF
 (TTM)
: 
-5.25
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-72.24%  ?ROIC
 (TTM)
: 
-94.66%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
4.46  ?Current Ratio
 (TTM)
: 
9.92

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Intellectual Property and Pipeline Positioning: The company operates in a specialized sector with a focus on proprietary technology, evidenced by its classification in the industry data. The company profile indicates a specific focus on its core business model, which, while pre-revenue or early-stage, suggests a potential for high-margin scalability if the technology is successfully commercialized.
  • Liquidity Position: Based on the balance sheet data, the company maintains a cash position relative to its current liabilities. The current ratio and quick ratio metrics (from Key Metrics) provide insight into its ability to meet short-term obligations. A current ratio significantly above 1.0 would indicate a strong ability to cover short-term debts, which is crucial for a company with negative net income.
  • Market Interest and Volatility: The stock exhibits a Beta (from Company Profile) that indicates higher volatility compared to the broader market. For the target audience of male investors aged 25-50 interested in wealth-building, this volatility presents potential for significant capital appreciation, particularly if the company hits key milestones. The average volume (volAvg) suggests sufficient liquidity for retail investors to enter and exit positions.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates RZLT intrinsic value between $0.12 – $0.26 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate RZLT Intrinsic Value

Common questions about RZLT valuation

Is Rezolute, Inc. (RZLT) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Rezolute, Inc. (RZLT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is RZLT a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether RZLT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is RZLT’s P/E ratio?

You can see RZLT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for RZLT?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is RZLT a good long-term investment?

Whether RZLT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Rezolute, Inc.

  • Rezolute, Inc. intrinsic value calculatorEstimate what the business is worth
  • Rezolute, Inc. 5-year outlookWhat has to go right, and what could go wrong
RZLT

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-6.67
MarketSnap

Trading Metrics:

Open: 4.09   Previous Close: 4.2
Day Low: 3.86   Day High: 4.23
Year Low: 1.07   Year High: 11.17
Price Avg 50: 4.05   Price Avg 200: 3.94
Volume: 2.474M   Average Volume: 1.56M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
13-11-2026 06:19
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
13-11-2026 06:18
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
08-10-2026 04:29
Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
Rezolute, Inc. (NASDAQ:RZLT) Receives $9.38 Average Price Target from Analysts
16-09-2026 01:29
Rezolute, Inc. (NASDAQ:RZLT) Receives $9.38 Average Price Target from Analysts

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze RZLT →
    • FindStock Picks / Stock Screener
    • Value · RZLTIntrinsic Value Calculator
    • Invest · RZLTInvestment Case
    • Hold · RZLT5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.